SEC Comment Letter 0000000000-25-003496 to Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc.
Date: April 1, 2025 · CIK: 0001799448 · Accession: 0000000000-25-003496
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286168
Letter
Re: Aligos Therapeutics, Inc. Registration Statement on Form S-3 Filed March 27, 2025 File No. 333-286168 Dear Lawrence M. Blatt:
April 1, 2025
Lawrence M. Blatt Chairman, President and Chief Executive Officer Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: John C. Williams, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2025 Lawrence M. Blatt Chairman, President and Chief Executive Officer Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 Re: Aligos Therapeutics, Inc. Registration Statement on Form S-3 Filed March 27, 2025 File No. 333-286168 Dear Lawrence M. Blatt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John C. Williams, Esq. </TEXT> </DOCUMENT>